The content aims to contribute spreading right information about COVID-19 Vaccine. The information are from World Health Organization and Philippine Department of Health. This may help my fellow Filipino to build his/her confidence to get vaccinated.

1. COVID-19
VACCINE
k n o w y o u r v a c c i n e

2. The best COVID-19 vaccine is the first one that is
available to you. Do not wait for a specific brand. All
currently authorized and recommended COVID-19
vaccines:
ü are safe,
ü are effective, and
ü reduce your risk of severe illness.

3. data from World Health Organization
The Different
Types of
COVID-19
VACCINES

6. The first way to make a vaccine
is to take the disease-carrying
virus or bacterium, or one very
similar to it, and inactivate or kill
it using chemicals, heat or
radiation. This approach uses
technology that’s been proven
to work in people – this is the
way the flu and polio vaccines
are made – and vaccines can be
manufactured on a reasonable
scale.
However, it requires special
laboratory facilities to grow the
virus or bacterium safely, can
h a v e a r e l a t i v e l y l o n g
production time, and will likely
require two or three doses to be
administered.
A live-attenuated vaccine uses a
living but weakened version of
the virus or one that’s very
similar. The measles, mumps
and rubella (MMR) vaccine and
the chickenpox and shingles
vaccine are examples of this
type of vaccine. This approach
uses similar technology to the
inactivated vaccine and can be
manufactured at scale. However,
vaccines like this may not be
s u i t a b l e f o r p e o p l e w i t h
compromised immune systems.
This type of vaccine uses a safe
virus to deliver specific sub-
parts – called proteins – of the
germ of interest so that it can
trigger an immune response
without causing disease. To do
this, the instructions for making
particular parts of the pathogen
of interest are inserted into a
safe virus. The safe virus then
serves as a platform or vector to
deliver the protein into the body.
The protein triggers the immune
response. The Ebola vaccine is a
viral vector vaccine and this type
can be developed rapidly.
Inactivated vaccine Live-attenuated vaccine Viral vector vaccine

8. A subunit vaccine is one that only uses the very specific parts (the
subunits) of a virus or bacterium that the immune system needs to
recognize. It doesn't contain the whole microbe or use a safe virus
as a vector. The subunits may be proteins or sugars. Most of the
vaccines on the childhood schedule are subunit vaccines, protecting
people from diseases such as whooping cough, tetanus, diphtheria
and meningococcal meningitis.
Protein Subunits

11. Unlike vaccine approaches that use either a weakened or dead whole microbe or parts of one,
a nucleic acid vaccine just uses a section of genetic material that provides the instructions for
specific proteins, not the whole microbe. DNA and RNA are the instructions our cells use to
make proteins. In our cells, DNA is first turned into messenger RNA, which is then used as the
blueprint to make specific proteins.
A nucleic acid vaccine delivers a specific set of instructions to our cells, either as DNA or
mRNA, for them to make the specific protein that we want our immune system to recognize
and respond to.
The nucleic acid approach is a new way of developing vaccines. Before the COVID-19
pandemic, none had yet been through the full approvals process for use in humans, though
some DNA vaccines, including for particular cancers, were undergoing human trials. Because
of the pandemic, research in this area has progressed very fast and some mRNA vaccines for
COVID-19 are getting emergency use authorization, which means they can now be given to
people beyond using them only in clinical trials.
Nucleic acid vaccine

12. VACCI NE
M A T R I X :
CURRENT
EVIDENCE
data as of 02 June 2021
data from Philippine Department of Health

13. PFIZER BIONTECH
mRNA
JANUARY 14,2021
MAY 31, 2021 (EXPANDED EUA TO INCLUDE 12 - 15
Y/O)
12 Y/O AND ABOVE
2 DOSES, 21 DAYS APART [A]
-80 TO -60 0C [A]
95 % AGAINST SYMPTOMATIC COVID-19 (CT
DONE FOR 16 Y/O AND ABOVE)
100 % AGAINST SYMPTOMATIC COVID-19 (CT
DONE FOR 12 TO 15 Y/O) [A][B]
• SHORT-TERM, MILD-TO-MODERATE PAIN AT
THE INJECTION SITE
• FATIGUE, HEADACHE [B]
References: [A] FDA Philippines EUA Approval [B] Publication in Journals for Phase III Interim Results [C] WHO Landscape and Tracker of COVID-19 Candidate
Vaccines [D] WHO Interim recommendations for EUL [E] Submission to FDA EUA Application [F] Clinicaltrials.gov [G] Center for Disease Control and Prevention [H]
Publication in Journals for Phase 1 and/or Phase 2 CT results [I] FDA Published Product Information Materials [J] US FDA Published Vaccine Fact Sheets

14. VIRAL VECTOR (NON-REPLICATING)
JANUARY 28, 2021
18 Y/O AND ABOVE
2 DOSES, 4-12 WEEKS APART [A]
2 TO 80C [A]
70.4 % AGAINST SYMPTOMATIC COVID-19 [A][B]
100 % AGAINST SEVERE COVID-19 [B]
• INJECTION SITE PAIN AND TENDERNESS
• FATIGUE, HEADACHE, FEVERISHNESS, MYALGIA
[B]
OXFORD ASTRAZENECA
References: [A] FDA Philippines EUA Approval [B] Publication in Journals for Phase III Interim Results [C] WHO Landscape and Tracker of COVID-19 Candidate
Vaccines [D] WHO Interim recommendations for EUL [E] Submission to FDA EUA Application [F] Clinicaltrials.gov [G] Center for Disease Control and Prevention [H]
Publication in Journals for Phase 1 and/or Phase 2 CT results [I] FDA Published Product Information Materials [J] US FDA Published Vaccine Fact Sheets

15. INACTIVATED VIRUS
FEBRUARY 22, 2021
18 Y/O AND ABOVE
2 DOSES, 28 DAYS APART [A]
2 TO 8 0C [A]
51 % OVERALL VE AGAINST SYMPTOMATIC
COVID-19
100 % AGAINST SEVERE COVID-19 AND
HOSPITALIZATION [D]
• LOCAL LYMPHADENOPATHY AT THE
INJECTION SITE,
• ALLERGIC REACTION THAT MAY BE CAUSED BY
ANY COMPONENT OF THE VACCINE
• CONVULSION (WITH OR WITHOUT FEVER) [ I ]
SINOVAC CORONAVAC
References: [A] FDA Philippines EUA Approval [B] Publication in Journals for Phase III Interim Results [C] WHO Landscape and Tracker of COVID-19 Candidate Vaccines
[D] WHO Interim recommendations for EUL [E] Submission to FDA EUA Application [F] Clinicaltrials.gov [G] Center for Disease Control and Prevention [H] Publication in
Journals for Phase 1 and/or Phase 2 CT results [I] FDA Published Product Information Materials [J] US FDA Published Vaccine Fact Sheets

16. VIRAL VECTOR (NON-REPLICATING)
MARCH 19, 2021
18 Y/O AND ABOVE
2 DOSES, 3 WEEKS APART [A]
-18 0C AND BELOW (FROZEN SOLUTION [A]
91.6 % AGAINST SYMPTOMATIC COVID-19 [B]
100 % AGAINST MODERATE OR SEVERE CASES [B]
• PAIN ON INJECTION SITE, HYPERTHERMIA,
SWELLING [B]
• HEADACHE, ASTHENIA, MUSCLE/JOINT PAIN,
MALAISE, SORE THROAT,
DIARRHEA,RHINORRHEA, LOSS OF APPETITE,
PAIN IN THE OROPHARYNX, NASAL
CONGESTION, COLDS, SNEEZING, COUGH [B]
GAMALEYA SPUTNIK V
References: [A] FDA Philippines EUA Approval [B] Publication in Journals for Phase III Interim Results [C] WHO Landscape and Tracker of COVID-19 Candidate Vaccines
[D] WHO Interim recommendations for EUL [E] Submission to FDA EUA Application [F] Clinicaltrials.gov [G] Center for Disease Control and Prevention [H] Publication in
Journals for Phase 1 and/or Phase 2 CT results [I] FDA Published Product Information Materials [J] US FDA Published Vaccine Fact Sheets

17. VIRAL VECTOR (NON-REPLICATING)
APRIL 19, 2021
18 Y/O AND ABOVE
1 DOSE [A]
2 TO 8 0C ( 3 MONTHS) [A]
66.1 - 66.9 % AGAINST CONFIRMED MODERATE
TO SEVERE/ CRITICAL COVID-19
~ 77 % - 85 % AGAINST SEVERE COVID-19 [J]
• INJECTION SITE PAIN, REDNESS, SWELLING
• TIREDNESS, HEADACHE, MUSCLE PAIN, CHILLS,
FEVER, NAUSEA [G]
JANSSEN
References: [A] FDA Philippines EUA Approval [B] Publication in Journals for Phase III Interim Results [C] WHO Landscape and Tracker of COVID-19 Candidate
Vaccines [D] WHO Interim recommendations for EUL [E] Submission to FDA EUA Application [F] Clinicaltrials.gov [G] Center for Disease Control and Prevention [H]
Publication in Journals for Phase 1 and/or Phase 2 CT results [I] FDA Published Product Information Materials [J] US FDA Published Vaccine Fact Sheets

18. INACTIVATED VIRUS
APRIL 19, 2021
18 Y/O AND ABOVE
2 DOSES, 28 DAYS APART [A]
2 TO 8 0C [A]
80.6 % AGAINST PCR-CONFIRMED SYMPTOMATIC
COVID-19 [E]
• HEADACHE, FATIGUE, FEVER, BODY ACHE,
ABDOMINAL PAIN, NAUSEA, VOMITING [E]
BHARAT BIOTECH
References: [A] FDA Philippines EUA Approval [B] Publication in Journals for Phase III Interim Results [C] WHO Landscape and Tracker of COVID-19 Candidate
Vaccines [D] WHO Interim recommendations for EUL [E] Submission to FDA EUA Application [F] Clinicaltrials.gov [G] Center for Disease Control and Prevention [H]
Publication in Journals for Phase 1 and/or Phase 2 CT results [I] FDA Published Product Information Materials [J] US FDA Published Vaccine Fact Sheets

19. mRNA
MAY 5, 2021
18 Y/O AND ABOVE
2 DOSES, 28 DAYS APART [B]
-25 TO -15 0C
2 TO 8 0C (30 DAYS) [E]
94.1 % AGAINST SYMPTOMATIC COVID-19 [B]
100 % AGAINST SEVERE COVID-19 [B]
• PAIN/ ERYTHEMA/ SWELLING ON INJECTION
SITE, AXILLARY LYMPHADENOPATHY [B]
• HEADACHE, FATIGUE, FEVER, MYALGIA,
ARTHRALGIA, NAUSEA, VOMITING, CHILLS [B]
MODERNA
References: [A] FDA Philippines EUA Approval [B] Publication in Journals for Phase III Interim Results [C] WHO Landscape and Tracker of COVID-19 Candidate
Vaccines [D] WHO Interim recommendations for EUL [E] Submission to FDA EUA Application [F] Clinicaltrials.gov [G] Center for Disease Control and Prevention [H]
Publication in Journals for Phase 1 and/or Phase 2 CT results [I] FDA Published Product Information Materials [J] US FDA Published Vaccine Fact Sheets

20. NOVAVAX
PROTEIN SUBUNIT
N/A (NO EUA APPLICATION YET)
N/A (NO EUA APPLICATION YET)
2 DOSES, 21 DAYS APART [C]
2 TO 8 0C [H]
AWAITING OFFICIAL PHASE III INTERIM JOURNAL
PUBLICATION
AWAITING OFFICIAL PHASE III INTERIM JOURNAL
PUBLICATION
References: [A] FDA Philippines EUA Approval [B] Publication in Journals for Phase III Interim Results [C] WHO Landscape and Tracker of COVID-19 Candidate
Vaccines [D] WHO Interim recommendations for EUL [E] Submission to FDA EUA Application [F] Clinicaltrials.gov [G] Center for Disease Control and Prevention
[H] Publication in Journals for Phase 1 and/or Phase 2 CT results [I] FDA Published Product Information Materials [J] US FDA Published Vaccine Fact Sheets

21. ü COVID-19 vaccines are safe and effective.
ü You may have side effects after vaccination, but these are normal.
ü It typically takes two weeks after you are fully vaccinated for the body to
build protection (immunity) against the virus that causes COVID-19.
ü If you are not vaccinated, find a vaccine. Keep taking all precautions until
you are fully vaccinated.
ü If you are fully vaccinated, you can resume activities that you did prior to
the pandemic. Learn more about what you can do when you have been fully
vaccinated.
What You Need to Know

22. FREQUENTLY
ASKED
QUESTIONS
data from Philippine Department of Health

23. How do vaccines prevent disease?
Vaccines mimic the virus or bacteria that causes disease and triggers the body’s creation of
antibodies. These antibodies will provide protection once a person is infected with the actual
disease-causing virus or bacteria.
How do vaccines differ?
Vaccines differ in their composition and how they trigger the immune response to create
antibodies. These antibodies protect the body from microorganisms and serve as protection
once a person gets infected with disease. Vaccines can be inactivated, weakened or killed
copies of the whole or part of the virus or bacteria, or genetic product (like mRNA vaccines)
that creates protein copies without causing disease.
What are the possible side effects of vaccination?
The possible side effects of a vaccine include pain, redness, itchiness or swelling at the
injection site (which may last a few hours); fever; feeling of weakness or fatigue; headache;
dizziness; diarrhea; or nausea. Consult the nearest healthcare professional if you experience
any of these.

24. Is vaccination mandatory?
No, vaccination is not mandatory. But the government highly encourages the public to get
vaccinated and be protected against preventable disease.
Why do we need to get vaccinated for COVID-19?
With the BIDA steps and observance of minimum public health standards, vaccination is an
important way to protect yourself from getting severe COVID-19.
When will the COVID-19 vaccine be available?
The government is currently in the advanced stages of negotiations with various vaccine
manufacturers. We expect the first vaccine supply to arrive in the first quarter of 2021
What is an Emergency Use Authorization (EUA)?
It is an authorization granted through a risk-based procedure for assessing unregistered
(under development) vaccines or drugs during public health emergencies of international
concern. It aims to expedite availability of the vaccine or drug to people affected by public
health emergency based on essential set of available quality, safety and efficacy performance
data.

25. Who will get the vaccines first?
Frontline health workers, senior citizens, indigent population, and uniformed personnel are
the priority groups to be vaccinated.
Why will the prioritized groups get the vaccine first?
With the initial limited supply, frontline health workers and uniformed personnel are
prioritized since they have higher risk of exposure while on duty and to allow them to
continue fulfilling their duties in both the public and private sectors. Vulnerable groups such
as the elderly and the indigent population, are prioritized guided by the principle of equity.
Can I purchase the vaccine from private clinics or pharmacies?
No, you cannot purchase COVID-19 vaccines from private clinics or pharmacies. At present,
only the government is duly authorized to procure and administer vaccines. Until a full
market authorization is issued by the Philippine FDA, any COVID-19 vaccine should not be
sold to the public.
Is the vaccine free for priority groups?
The cost of vaccines for priority groups will be shouldered by the Philippine government.

26. If I am not part of the priority group, how will I get access to the vaccine?
The government is continuing negotiations to ensure adequate vaccine supply for all Filipinos,
including those not in the priority groups.
Are the COVID-19 vaccines safe and effective?
COVID-19 vaccines that are granted with Emergency Use Authorization (EUA) by the Food and
Drug Administration (FDA) are considered safe and effective based on the available evidence to date.
Are there risks for complications when given the COVID-19 vaccine?
Yes, like all other vaccines, there are risks of complications BUT SEVERE OR LIFE-THREATENING
REACTIONS ARE EXTREMELY RARE. The benefit of protection against severe COVID-19 is greater
than the risk. Anyone who will get the vaccine will be properly evaluated and closely monitored by
health professionals to further minimize any risk.
What can we do while waiting for the vaccine?
We urge the public to be more vigilant with the information found online. Let us make it a habit to
fact check and verify with reliable sources (DOH Facebook page, DOH website, WHO website, PIA
website) regarding new information. Continue observing the minimum public health standards to
prevent further transmission of the virus.

27. THANK YOU :)
KEEP SAFE!

28. RESOURCES
WORLD HEALTH ORGANIZATION
PHILIPPINE DEPARTMENT OF HEALTH
SLIDESGO (PRESENTATION TEMPLATE)